Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix (NASDAQ:OCUL) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.

Which has better earnings and valuation, OCUL or GRFS?

Grifols has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocular Therapeutix	$63.72M	21.29	-$80.74M	-$1.26	-6.77
Grifols	$7.21B	0.67	$64.20M	$1.17	6.00

Does the MarketBeat Community believe in OCUL or GRFS?

Ocular Therapeutix received 92 more outperform votes than Grifols when rated by MarketBeat users. Likewise, 70.27% of users gave Ocular Therapeutix an outperform vote while only 56.09% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
Ocular Therapeutix	Outperform Votes 442 70.27%	Underperform Votes 187 29.73%
Grifols	Outperform Votes 350 56.09%	Underperform Votes 274 43.91%

Does the media prefer OCUL or GRFS?

In the previous week, Ocular Therapeutix had 6 more articles in the media than Grifols. MarketBeat recorded 12 mentions for Ocular Therapeutix and 6 mentions for Grifols. Grifols' average media sentiment score of 1.38 beat Ocular Therapeutix's score of 0.98 indicating that Grifols is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ocular Therapeutix	6 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders have more ownership in OCUL or GRFS?

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.5% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 0.2% of Grifols shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has more risk and volatility, OCUL or GRFS?

Ocular Therapeutix has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Is OCUL or GRFS more profitable?

Grifols has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -283.74%. Grifols' return on equity of 0.00% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocular Therapeutix	-283.74%	-45.18%	-30.87%
Grifols	N/A	N/A	N/A

Do analysts recommend OCUL or GRFS?

Ocular Therapeutix presently has a consensus target price of $16.38, suggesting a potential upside of 91.97%. Given Ocular Therapeutix's higher probable upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocular Therapeutix	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Summary

Grifols beats Ocular Therapeutix on 10 of the 19 factors compared between the two stocks.